AAPS 2016 - blogFrom nanoemulsions, nanosuspensions, vaccines and adjuvants to drug formulation and release development, this year’s American Association of Pharmaceutical Scientists (AAPS) National Biotech Conference has the strapline: “Advancing health through innovation in biotherapeutics“.

Come visit us at booth #400 at the Hynes Convention Center in Boston, Massachusetts, to find out what Malvern is doing to innovate in the analytical biotech sector on May 16 – 18, 2016.

Poster Session highlights

There are two poster sessions at the meeting (Monday and Tuesday, Hynes Convention Center – Hall D), and quite a few posters, with presenters from Mercer University, Liverpool John Moores University, Malvern on Research Gate, and Duquesne University, contain data acquired using the Zetasizer. Here is a list containing links to the poster abstracts:

  • M 1001 – Formulation and Characterization of Polycaprolactone/Poloxamer Nanoparticles for Tumor Targeting. Size and charge of Polycaprolactone (PCL) nanoparticles were measured with the Zetasizer. Physical stability of the nanosuspensions was monitored by measuring the size of nanoparticles over a 14-day period. Oswald ripening was observed and chitosan enhanced the stability of the nanosuspensions.
  • M 1013 – Pulmonary Delivery of Therapeutic miR-146a Nanoparticles. PGA-co-PDL nanoparticles were characterized for size, polydispersity index (PDI) and zeta potential (ZP) using a Zetasizer. Size and charge depended on the concentration of DOTAP. With absorbed miRNA these novel miRNA-NPs show potential as a pulmonary delivery system.
  • M 1032 – Augmentation of Co-stimulatory Molecule Expression by Adjuvants in Dendritic Cells following Exposure to Influenza M2e VLP Micro Particulate Vaccine. The Malvern Zetasizer was used to characterize the formulation for size and surface charge.
  • M 1033 – A Novel Microparticulate Fusion Protein Virus-like Particle (F-VLP) Vaccine against the Respiratory Syncytial Virus (RSV). The Malvern Zetasizer was used to characterize the microparticulate vaccine formulation. The particle size of the F-VLP microparticulate vaccine ranged between 1-2 μm and the average surface charge was found to be -25.39 mV.
  • M 1089 – Screening for Immunogenic Risk Potential–The Bioformulation Stability Profile. In this case study of assessing Innovator vs. Biosimilar mAb Stability to minimize immunogenic risk, the Zetasizer determined Stokes radius, hydrodynamic interaction parameter, aggregation onset temperature, 2nd virial coefficient, and additional information from NTA and DSC was part of the study.
  • T 2012 – Nanoemulsions as Carriers for MOM I PP: A Novel Glioblastoma Multiform Drug. Nanoemulsions were tested for long term stability (both size and zeta potential), colloidal stability under cell culture relevant conditions, drug loading, and drug release. All size and zeta potential measurements were performed via light scattering (DLS & ELS) (Zetasizer Nano, Malvern).

Check out the posters, and feel free to come and visit us on our booth (#400 Floor plan) to find out how Zetasizing might help your innovative project.

Previously

If you have any questions, please email me at ulf.nobbmann@malvern.com. Thanks! While opinions expressed are generally those of the author, some parts may have been modified by our editorial team.